Contents:

ALZHEIMER’S AND PARKINSON’S DISEASES A GLOBAL STRATEGIC BUSINESS REPORT CONTENTS I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations I-1 Disclaimers I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3 Product Segments I-3 Anti-Alzheimer’s Disease Drugs I-3 Cholinesterase Inhibitors I-3 NMDARA I-4 Anti-Parkinson’s Disease Drugs I-4 Dopaminergic Agents (Levodopa/Carbidopa) I-4 Dopamine Agonists I-4 Other PD Drugs (Include COMT Inhibitors, MOA-B Inhibitors, and Dopamine Amplifiers) I-5 COMT Inhibitors I-5 MAO-B Inhibitors I-5 Dopamine Amplifiers I-5 II. Executive Summary 1. Outlook II-1 Current and Future Analysis II-1 2. Neurodegenerative Diseases Market - A Brief Overview II-2 Key Brands in NDD Market II-2 Table 1: Leading Drugs in the Global Neurodegenerative Disease Market (2004): Percentage Breakdown by Sales Revenues for Razadyne, Aricept, Exelon, Namenda, Sifrol / Mirapex, Requip, Cabaser, Madopar, Siemet, Permax, and Others (includes corresponding Graph/Chart) II-3 Factors Affecting Market II-3 Major Growth Drivers II-3 Major Growth Inhibitors II-3 Market Trends II-4 High Prevalence Rates Drive Market Growth II-4 Rapid Growth of Ageing Population II-4 Price Hikes and Government Caps II-4 Combination Therapy Gaining Ground II-5 Research & Development II-5 Future Holds Promise II-5 3. Alzheimer’s Market Overview II-6 A Peek at Anti-AD Drug Market II-6 Impact of Dementia II-6 Epidemiology II-6 Table 2: World Alzheimer’s Disease Prevalence for Years 2000 through 2010: Number of Patients in Thousands by Country/Region for US, Canada, Japan, Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), and Rest of World (includes corresponding Graph/Chart) II-7 Table 3: Alzheimer’s Disease Prevalence in Top Seven Countries (US, Japan, Germany, France, UK, Italy, and Spain) for Years 2001 through 2010: Number of Patients (in ‘000) Diagnosed and Treated by Disease Severity (Mild Stage, Moderate Stage, and Late Stage) (includes corresponding Graph/Chart) II-8 Table 4: Alzheimer’s Disease Diagnosis in Top Seven Countries (2005): Percentage of Diagnosed Patients in the US, Japan, Germany, France, Italy, Spain, and the UK (includes corresponding Graph/Chart) II-8 Patient Growth Drivers II-8 Demographics Spell Opportunities II-8 High Growth Rates for AD Drugs II-9 The Impact of Aricept II-9 Epic of NMDARA II-9 Strengths II-10 Weaknesses II-10 Future Therapies II-11 How Successful will the Late Stage Therapies be? II-11 A Geographic Milieu II-11 US II-11 Europe II-11 Japan II-11 Alternative Drug Delivery Technologies Gaining Ground II-12 Transdermal Patch II-12 Domination of Acetyl Cholinesterase Inhibitors II-12 Dramatic Changes in Market Lie Ahead II-12 Advances in Next-Generation Treatments II-12 Beta Amyloid Hypothesis II-13 Growth Drivers II-13 Ageing Baby Boomers Drive AD Market II-13 Table 5: AD Frequency Rate (%) (includes corresponding Graph/Chart) II-13 New Hypothesis Enables Effective Treatment II-14 Unmet Medical Needs Drive Market Growth II-14 Growth Inhibitors II-14 Link with Other Aliments II-14 Misdiagnosis II-14 Patient Awareness II-14 Medical Refunds II-14 Competitive Landscape II-15 Pharmaceutical Majors Rule the Market II-15 Eisai/Pfizer II-15 Novartis II-15 Shire/Johnson & Johnson II-15 Lundbeck/Forest II-16 Ipsen and UCB II-16 Table 6: Leading Brands in the Global Anti- Alzheimer’s Drug Market (2005): Percentage Breakdown by Sales Revenues for Aricept, Exelon, Razadyne, Axura, Ebixa, Namenda, and Others (includes corresponding Graph/Chart) II-16 Year of Approval of AD Drugs in Leading Countries II-17 Compounds in Pipeline II-17 Outlook for AD Drugs Market II-18 4. Parkinson’s Disease Market Overview II-19 An Alluring Market II-19 Prevalence II-19 Table 7: World Parkinson’s Disease Prevalence for Years 2000 through 2010: Number of Patients in Thousands by Country/Region for US, Canada, Japan, Europe (Germany, France, UK, Italy, Spain, Rest of Europe), and Rest of World (includes corresponding Graph/Chart) II-19 Current Treatments II-20 New Medicines on the Horizon II-20 New Findings II-20 Product Launches Through 2009 II-20 Dominance of Dopamine Agonists II-20 Revival Revels in Other Anti-PD Drugs Segment II-21 COMT Inhibitors Growing Fastest II-21 Key Market Drivers II-21 Rising Awareness Magnifies Patient Base II-21 Emergence of Dopamine Agonists as First Line Treatment Drives Market Growth II-21 The Debut of Stalevo II-21 Unmet Clinical Needs Show Mammoth Prospects II-21 Key Market Inhibitors II-22 Limitations of Existing Medicines Inhibit Market Growth II-22 Under-Diagnosis Restrains Market Potential II-22 Generic Competition from L-Dopa and Carbidopa Curbs Market Growth II-22 Restricted Term of Dopamine Agonists Usage Delays Market Growth II-22 5. Disease Overview II-23 Alzheimers Disease II-23 Definition II-23 The Cause II-23 Finding AD II-23 Prevention II-23 Treatment II-24 Parkinson’s Disease II-24 Definition II-24 Pathophysiology II-24 Diagnosis II-25 Prevalence II-25 Treatment II-25 Surgical Intervention II-25 6. Drug Classification II-26 Anti-Alzheimer’s’ Disease Drugs II-26 NMDARA II-26 Memantine II-27 Cholinesterase Inhibitors (ChEIs) II-27 Donepezil (Aricept) II-27 Rivastigmine (Exelon) II-27 Galantamine Hydrobromide (Razadyne) II-28 Tacrine (Cognex) II-28 Other Alternatives II-28 Vitamin E II-28 Estrogen Therapy II-28 Anti-Inflammatory Drugs II-29 NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) II-29 Antioxidants II-29 Vaccine II-29 Gingko Biloba II-29 Pure Medical Nicotine II-29 Anti-Parkinson’s Disease Drugs II-29 Dopaminergic agents II-30 Levodopa/Carbidopa II-30 Dopamine Agonists II-30 Pergolide/Permax II-30 Bromocriptine/Parlodel II-30 Ropinirole/Requip II-30 Pramipexole/Mirapex II-31 Cabergoline/Dostinex II-31 Apomorphine/Apokyn II-31 Other Dopamine Agonists II-31 Other PD Drugs II-31 COMT Inhibitors II-31 Tolcapone (Tasmar) II-31 Entacapone (Comtan) II-32 MAO-B Inhibitors II-32 Dopamine Amplifiers II-32 Anticholinergics II-32 7. Future Therapies II-33 Alzheimer’s Disease II-33 Key Pipeline Products II-33 Phenserine II-33 Ropern II-33 Alzhemed II-34 MEM 1003 II-34 Ampakine Compounds II-34 Parkinson’s Disease II-34 Key Pipeline Products II-34 Adenosine A2a Antagonist II-35 Spheramine® II-35 Safinamide II-35 O-1369 II-36 8. New Findings II-37 Risedronate Minimizes Risk of Hip Fractures in PD Patients II-37 Researchers Identify New Genes Responsible for AD II-37 Researchers Establish a New Link Between Loneliness and AD II-37 Researchers Try to Identify Early Stages of AD II-37 SORL1 - The New Gene Found to be Responsible for AD II-38 Scientists Conduct Research Work on CERE-120 Gene Therapy II-38 Researchers Find New Snail Toxin for Nervous System Disorders II-38 Researchers Study Anti-PD Properties of Nicotine II-38 Researchers Establish New Link Between Pesticides and PD II-38 Study Relates AD to the Quantity of Amyloid Protein II-39 Researchers Establish Effectiveness of Gene Therapy on AD Patients II-39 Scientists Use Electric Current to Treat PD Patients II-39 Scientists Prove Earlier Assumptions Wrong II-39 Scientists Discover 2 Distinct Types of MCIs II-40 9. Recent Industry Activity II-41 Eisai Acquires MGI Pharma II-41 Eli Lilly Begins Phase III Clinical Trial of Alzheimers Disease Treatment II-41 Merz Licenses Anti-Alzheimer’s Drug Technology from TAU II-41 Eisai Acquires Morphotek II-41 Transition Therapeutics Acquires NeuroMedix II-41 Evotec Teams Up with Boehringer Ingelheim II-41 Siemens Signs Partnership Agreement with Wyeth II-42 Digilab Receives Notice of Allowance for New Alzheimers Biomarker II-42 Pfizer Joins Forces with Genizon II-42 Intellect Signs Licensing Agreement with IBL II-42 Boehringer Ingelheim signs R&D agreement with Ablynx II-42 Avicena Teams Up with NINDS for Phase III Trial of PD-02 II-43 Prana Begins Phase II clinical trial for PBT2 II-43 Idera Teams Up with Merck II-43 Merck Signs R&D Agreement with Neuroptix II-44 Neuro-Hitech Takes Over Q-RNA II-44 Neurogen Inks Licensing Agreement with Wyeth II-44 Acumen Revises License Agreement with Merck II-44 Newron Begins 2nd Phase III clinical trial for Safinamide II-44 Newron Inks Global Licensing Agreement with Serono II-45 Pfizer Inks License Agreement with TransTech II-45 CeNeS Renews R&D Agreement with Tripos II-45 Athenagen Acquires Zapaq II-45 Neuren Starts Pre-clinical Studies of Anti-PD Drug - NNZ-2591 II-45 Teva Receives Health Canada Clearance for Azilect II-46 Valeant Introduces Zelapar Anti-PD Tablets in the US II-46 Merck to Halt Further Development of Anti-PD Drug Called Sarizotan II-46 Amarin Obtains Global Rights for New Apomorphine Formulation II-46 FDA Clears Exelon for Parkinsons Disease II-46 Neuropharma Receives German Clearance for Phase 1 Clinical Trials of NP031112 II-47 Pfizer Takes Over Rinat II-47 TorreyPines Begins 2nd Phase-I clinical trial for NGX267 II-47 Kyowa Hakko Inks Licensing Agreement with Britannia II-47 Schwarz Pharma Receives EMEA Clearance for Neupro II-47 Evotec Inks Licensing Agreement with Roche II-48 RheoGene Receives Funds from MJFF II-48 Eisai Initiates Phase I clinical trial for E2012 II-48 Apokyn(R) Receives Approval in North America II-48 FDA Approves Azilect II-48 Voyager Completes Phase II Study for of Leuprolide Acetate II-49 New Discovery for the Treatment of Alzheimers Disease in Canada II-49 Ortho-McNeil Launches Razadyne™ ER II-49 Flurizan Enters Phase II Clinical Trials II-50 Axonyx Releases Supplementary Results of Phase III Trial for Phenserine II-50 Predix Pharmaceuticals Starts Phase Ib Trials of 5-HT4 Agonist II-50 BrainStorm Pronounces Advantages of GDNF Producing Stem Cells in Parkinsons Animal Models II-50 Predix’s PRX-03140 Completes First Clinical Trial in Alzheimers Disease II-51 Galapagos and Senexis Expand Collaboration II-51 Novartis Joins Forces with Ono to Develop and Market AD Transdermal Patch II-51 Neurologix Posts Interim Results of Phase I Gene Therapy II-51 GB Therapeutics Receives License for CHF1512 II-51 Alzhemed™ Begins Phase III Trials II-51 Newron Commences Phase III Trial With Safinamide II-52 Ceregene Bags FDA Approval for Gene Therapy Alzheimers Study II-52 Memantine Drug Receives Approval from FDA for Treatment of Alzheimer’s II-52 FDA Grants Fast Track Designation II-52 Ester Neurosciences Joins Forces with Pharmacopeia II-52 10. Focus on Select Players II-53 Boehringer Ingelheim (Germany) II-53 Bristol-Myers Squibb Co. (USA) II-53 Eisai Inc. (USA) II-53 Eli Lilly and Company (USA) II-54 Forest Pharmaceuticals (USA) II-54 GlaxoSmithKline PLC (UK) II-54 H. Lundbeck A/S (Denmark) II-55 Merz Pharmaceuticals GMBH (Germany) II-55 Novartis AG (Switzerland) II-55 Ortho-McNeil Neurologics, Inc. (USA) II-56 Pfizer Inc (US) II-56 Roche (Switzerland) II-56 Shire Pharmaceuticals Group PLC (UK) II-56 Valeant Pharmaceuticals International (USA) II-57 11. Global Market Perspective II-58 Table 8: World Recent Past, Current & Future Market Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-58 Table 9: World Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-59 Table 10: World 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart) II-60 Table 11: World Recent Past, Current & Future Market Analysis for Anti-Alzheimer’s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-61 Table 12: World Long-term Projections for Anti-Alzheimer’s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-62 Table 13: World Recent Past, Current & Future Market Analysis for Anti-Alzheimer’s Disease Drugs by Product Segment -Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-63 Table 14: World Long-term Projections for Anti-Alzheimer’s Disease Drugs by Product Segment -Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-63 Table 15: World 10-Year Perspective for Anti-Alzheimer’s Disease Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart) II-64 Table 16: World 10-Year Perspective for Anti-Alzheimer’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) Markets for 2003, 2008 & 2012 II-64 Table 17: World Recent Past, Current & Future Market Analysis for Cholinesterase Inhibitors by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-65 Table 18: World Long-term Projections for Cholinesterase Inhibitors by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-66 Table 19: World 10-Year Perspective for Cholinesterase Inhibitors by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart) II-67 Table 20: World Recent Past, Current & Future Market Analysis for NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2002 through 2010 (includes corresponding Graph/Chart) II-68 Table 21: World Long-term Projections for NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-69 Table 22: World 9-Year Perspective for NMDARA (N-methyl, D-Aspartate Receptor Antagonists)) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2004, 2008 & 2012 (includes corresponding Graph/Chart) II-70 Table 23: World Recent Past, Current & Future Market Analysis for Anti-Parkinson’s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-71 Table 24: World Long-term Projections for Anti-Parkinson’s Disease Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-72 Table 25: World Recent Past, Current & Future Market Analysis for Anti-Parkinson’s Disease Drugs by Product Segment - Dopaminergic agents, Dopamine Agonists, and Other PD Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-73 Table 26: World Long-term Projections for Anti-Parkinson’s Disease Drugs by Product Segment - Dopaminergic agents, Dopamine Agonists, and Other PD Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-73 Table 27: World 10-Year Perspective for Anti-Parkinson’s Disease Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart) II-74 Table 28: World 10-Year Perspective for Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart) II-74 Table 29: World Recent Past, Current & Future Market Analysis for Dopaminergic Agents by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-75 Table 30: World Long-term Projections for Dopaminergic Agents by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-76 Table 31: World 10-Year Perspective for Dopaminergic Agents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart) II-77 Table 32: World Recent Past, Current & Future Market Analysis for Dopamine Agonists by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-78 Table 33: World Long-term Projections for Dopamine Agonists by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-79 Table 34: World 10-Year Perspective for Dopamine Agonists by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart) II-80 Table 35: World Recent Past, Current & Future Market Analysis for Other PD Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) II-81 Table 36: World Long-term Projections for Other PD Drugs by Geographic Region - US, Canada, Japan, Europe, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-82 Table 37: World 10-Year Perspective for Other PD Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart) II-83 III. MARKET 1. The United States III-1 A.Market Analysis III-1 Current & Future Analysis III-1 AD Market Overview III-1 Approval of Cholinesterase Inhibitors for MCI to Drive Market III-1 Competitive Landscape III-2 Table 38: Leading Therapeutics in the North American Alzheimer’s Disease Market (2005 & 2004): Percentage Breakdown by New Prescription for Aricept, Exelon, Namenda, and Razadyne (includes corresponding Graph/Chart) III-2 Status of AD Drugs III-3 New Products in Clinical Trails III-3 Prevalence III-4 Table 39: Alzheimer’s Disease Prevalence in the US for Years 2005 through 2010 (includes corresponding Graph/Chart) III-4 PD Therapies Market III-4 Levodopa/Carbidopa on Declining Spree III-4 Competition III-4 Table 40: Leading Brands in the US PD Therapeutics Market (2004-2006E): Percentage Breakdown by Prescription for Generic Amantadine, Generic Benzitropine, Generic Levodopa/Carbidopa, Comtan, Mirapex, Requip, Generic Selegiline, Sinemet/Sinemet CR, Rasagiline, and Others (includes corresponding Graph/Chart) III-5 Patent Expiry Status III-5 Patent Expiry Status of Parkinson’s Disease Drugs in the US III-5 New Brands and Pipeline Analysis III-6 PD Prevalence III-6 New Findings III-6 Strategic Corporate Developments III-8 Key Players III-15 B.Market Analytics III-18 Table 41: US Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-18 Table 42: US Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-19 Table 43: US 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart) III-20 2. Canada III-21 A.Market Analysis III-21 Current & Future Analysis III-21 Prevalence III-21 Strategic Corporate Developments III-21 B.Market Analytics III-22 Table 44: Canadian Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-22 Table 45: Canadian Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-23 Table 46: Canadian 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart) III-24 3. Japan III-25 A.Market Analysis III-25 Current & Future Analysis III-25 Prevalence III-25 Strategic Corporate Developments III-25 B.Market Analytics III-26 Table 47: Japanese Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-26 Table 48: Japanese Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-27 Table 49: Japanese 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart) III-28 4. Europe III-29 A.Market Analysis III-29 Current & Future Analysis III-29 Prevalence III-29 Alzheimer’s Disease III-29 Table 50: European Alzheimer’s Disease Prevalence For Years 2000 through 2010: Number of Patients (in ‘000) by Country/Region for Germany, France, UK, Italy, Spain, and Rest of Europe (includes corresponding Graph/Chart) III-30 Parkinson’s Disease III-30 Table 51: European Parkinson’s Disease Prevalence For Years 2000 through 2010: Number of Patients (in ‘000) by Country/Region for Germany, France, UK, Italy, Spain, and Rest of Europe (includes corresponding Graph/Chart) III-30 Competitive Scenario III-31 Table 52: Leading Brands in the European Alzheimer’s Disease Market (2005): Percentage Breakdown by New Prescription for Aricept, Ebixa/Auxura, Exelon, and Razadyne (includes corresponding Graph/Chart) III-31 Strategic Corporate Developments III-31 B.Market Analytics III-32 Table 53: European Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region - Germany, France, UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-32 Table 54: European Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region - Germany, France, UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-33 Table 55: European Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-34 Table 56: European Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-35 Table 57: Rest of Europe 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for Germany, France, UK, Italy, Spain, and Rest of Europe Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart) III-36 Table 58: Rest of Europe 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart) III-37 4a. Germany III-38 A.Market Analysis III-38 Current & Future Analysis III-38 Prevalence III-38 Strategic Corporate Developments III-38 Key Players III-39 B.Market Analytics III-40 Table 59: German Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-40 Table 60: German Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-41 Table 61: German 10-Year Perspective for Anti- Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart) III-42 4b. France III-43 A.Market Analysis III-43 Current & Future Analysis III-43 Prevalence III-43 B.Market Analytics III-44 Table 62: French Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti- Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-44 Table 63: French Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti- Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-45 Table 64: French 10-Year Perspective for Anti- Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart) III-46 4c. United Kingdom III-47 A.Market Analysis III-47 Current & Future Analysis III-47 Prevalence III-47 New Findings III-47 Strategic Corporate Developments III-48 Key Players III-48 B.Market Analytics III-50 Table 65: UK Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti- Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-50 Table 66: UK Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti- Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-51 Table 67: UK 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart) III-52 4d. Italy III-53 A.Market Analysis III-53 Current & Future Analysis III-53 Prevalence III-53 Strategic Corporate Developments III-53 B.Market Analytics III-54 Table 68: Italian Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-54 Table 69: Italian Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugsby Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-55 Table 70: Italian 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart) III-56 4e. Spain III-57 A.Market Analysis III-57 Current & Future Analysis III-57 Prevalence III-57 B.Market Analytics III-58 Table 71: Spanish Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-58 Table 72: Spanish Long-term Projections for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-59 Table 73: Spanish 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart) III-60 4f. Rest of Europe III-61 A.Market Analysis III-61 Current & Future Analysis III-61 Prevalence III-61 New Findings III-61 Strategic Corporate Developments III-61 Key Players III-62 B.Market Analytics III-64 Table 74: Rest of Europe Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti- Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-64 Table 75: Rest of Europe Long-term Projections for Anti-Alzheimer’s and Anti- Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-65 Table 76: Rest of Europe 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart) III-66 5. Rest of World III-67 A.Market Analysis III-67 Current & Future Analysis III-67 Prevalence III-67 Strategic Corporate Developments III-67 B.Market Analytics III-69 Table 77: Rest of World Recent Past, Current & Future Analysis for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart) III-69 Table 78: Rest of World Long-term Projections for Anti-Alzheimer’s & Anti-Parkinson’s Disease Drugs by Product Segment - Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-70 Table 79: Rest of World 10-Year Perspective for Anti-Alzheimer’s and Anti-Parkinson’s Disease Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer’s Disease Drugs (Cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), Anti-Parkinson’s Disease Drugs (Dopaminergic Agents, Dopamine Agonists, and Other PD Drugs) Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart) III-71 IV. COMPETITIVE LANDSCAPE

Companies Mentioned

The Companies mentioned inside this report include: Amarin Corporation PLC (UK) Amorfix Life Sciences Ltd (Canada) Apotex, Inc (Canada) Asterand PLC (UK) Avicena Group, Inc (USA) Avigen, Inc (USA) Axonyx, Inc (USA) Boehringer Ingelheim GmbH (Germany) Boehringer Ingelheim Pharmaceuticals, Inc (USA) Boehringer Ingelheim (Egypt) Brainstorm Cell Therapeutics, Inc (USA) Bristol-Myers Squibb Company (USA) Bristol-Myers Squibb GmbH & Co KgaA (Germany): CeNeS Pharmaceuticals PLC (England) Cephalon, Inc (USA) Ceregene, Inc (USA) Cita Neuropharmaceuticals, Inc (Canada) CMI India Pvt, Limited (India) Comtan (Canada) Desitin Arzneimittel GmbH (Germany) Draxis Health, Inc (Canada) Eisai Co, Ltd (Japan) Eisai, Inc (USA) Eli Lilly and Company (USA) Eli Lilly and Company Limited (UK) Epix Pharmaceuticals (USA) Ester Neurosciences Ltd (Israel) Exelon (USA) F Hoffmann-La Roche Ltd (Switzerland) Forest Laboratories, Inc (USA) Forest Pharmaceuticals Inc (USA) Gerolymatos P N, SA (Greece) GlaxoSmithKline PLC (UK) GlaxoSmithkline NZ Ltd (New Zealand) Glaxosmithkline SpA (Italy) H Lundbeck AS (Denmark) Lundbeck Espana SA (Spain) Impax Laboratories, Inc (USA) Johnson & Johnson (USA) Johnson & Johnson Pharmaceutical Research & Development LLC (USA) Janssen LP (USA) Kyowa Hakko Kogyo Co, Ltd (Japan) Medtronic, Inc (USA) Merck & Co, Inc (USA) Merz Pharmaceuticals GmbH (Germany) Mirapex (USA) Myriad Genetics, Inc (USA) Neuren Pharmaceuticals Limited (New Zealand) Neurim Pharmaceuticals () Ltd (Israel) Neurochem, Inc (Canada) Neurologix, Inc (USA) Newron Pharmaceuticals SpA (Italy) Novartis AG (Switzerland) Novartis Pharmaceuticals Corporation (USA) Novartis Deutschland GmbH (Germany) Novartis Pharma GmbH (Germany) NsGene A/S (Denmark) Nymox Pharmaceutical Corporation (Canada) Orion Corporation (Finland) Ortho-McNeil Neurologics, Inc (USA) Pfizer, Inc (USA) Pfizer Australia Pty, Ltd (Australia) Pfizer Manufacturing Belgium NV (Belgium) Pharmacopeia Drug Discovery, Inc (USA) Pharmaline Sal (Lebanon) ReGen Therapeutics PLC (UK) ReNeuron Ltd (UK) Richter Gedeon (Hungary) Samaritan Pharmaceuticals, Inc (USA) Sanofi-Aventis (France) Schering España SA (Spain) Sciele Pharma, Inc (USA) Senexis Limited (UK) Shire Pharmaceuticals Group PLC (UK) Somerset Pharmaceuticals, Inc (USA) Stalevo (USA) StemCells, Inc (USA) Terapia (Romania) Teva Pharmaceutical Industries Ltd (Israel) Titan Pharmaceuticals, Inc (USA) TorreyPines Therapeutics (USA) Unipharm Ltd (Israel) Valeant Pharmaceuticals International (USA) Vernalis PLC (UK) Voyager Pharmaceutical Corporation (USA) Wyeth (USA) Zentiva AS Praha (Czech Republic) Zhejiang Yixin Pharmaceutical Company Limited (China)